Literature DB >> 2935329

Effects of new inotropic agents on Ca++ sensitivity of contractile proteins.

J C Rüegg.   

Abstract

In cardiac muscle the relationship between contraction and the intracellular free calcium concentration is not unique but may vary over a wide range, as when influenced by new positive inotropic drugs. Modulation of the sensitivity of myofilaments to calcium may be studied in chemically skinned fibers devoid of a functional sarcoplasmic reticulum and in which the ionic composition of the interfilament space can be controlled and influenced at will. At low levels of activation with Ca++ (1 microM), the new nonglycosidic, nonadrenergic cardiotonic drugs sulmazole (AR-L 115 BS) and pimobendane (UD-CG 115 BS) increase calcium-induced contraction of skinned mammalian cardiac fibers by 30% to 50% in concentrations at which they exert a positive inotropic effect in vivo. The effect on skinned fibers is due to an increase in the sensitivity of the myofilaments to calcium and, at least in the case of sulmazole, may be attributed to an increase in calcium affinity of troponin. Calcium-induced contraction of skinned fibers from vertebrate smooth muscle that lacks troponin is not activated by sulmazole and pimobendane. Thus the positive inotropic action of these new cardiotonic drugs might be accounted for in part by their calcium-sensitizing action of myofilaments, although other mechanisms that increase intracellular free calcium may be involved as well.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935329

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  Selective updates on mechanisms of action of positive inotropic agents.

Authors:  G Grupp
Journal:  Mol Cell Biochem       Date:  1987-08       Impact factor: 3.396

Review 2.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

3.  E-1020, a water soluble imidazopyridine, has direct effects on Ca(2+)-dependent force and ATP hydrolysis of canine and bovine cardiac myofilaments.

Authors:  F M Powers; K A Palmiter; R J Solaro
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

4.  Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.

Authors:  G Hasenfuss; C Holubarsch; H W Heiss; B Rattert; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

5.  Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.

Authors:  K M Chu; S M Shieh; O Y Hu
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Improved ventricular function by enhancing the Ca++ sensitivity in normal and stunned myocardium of isolated rabbit hearts.

Authors:  B Korbmacher; U Sunderdiek; G Arnold; H D Schulte; J D Schipke
Journal:  Basic Res Cardiol       Date:  1994 Nov-Dec       Impact factor: 17.165

Review 7.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

Review 8.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

Review 9.  Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view.

Authors:  R J Hajjar; J K Gwathmey
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

Review 10.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.